Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON)

OBJECTIVES: To assess baricitinib on patient-reported outcomes (PROs) in patients with moderately to severely active rheumatoid arthritis, who had insufficient response or intolerance to ≥1 tumour necrosis factor inhibitors (TNFis) or other biological disease-modifying antirheumatic drugs (bDMARDs)....

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ann Rheum Dis
Main Authors: Smolen, Josef S, Kremer, Joel M, Gaich, Carol L, DeLozier, Amy M, Schlichting, Douglas E, Xie, Li, Stoykov, Ivaylo, Rooney, Terence, Bird, Paul, Sánchez Bursón, Juan Miguel, Genovese, Mark C, Combe, Bernard
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2017
Assuntos:
Clinical and Epidemiological Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5530360/
https://ncbi.nlm.nih.gov/pubmed/27799159
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/annrheumdis-2016-209821
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados